Scientific deep-dive
GLP-1 Drugs and Suicidal Thoughts: The Warning Came Off in 2026
In February 2026 the Suicidal Behavior and Ideation section was removed from the Wegovy, Zepbound and Saxenda labels, after three large studies looked for a signal and none found one.
In February 2026 the Suicidal Behavior and Ideation section was removed from the Wegovy, Zepbound and Saxenda labels.[4][5][6] Each of those labels now contains a single mention of the word, in the table recording that the section is gone. That happened after three large studies looked for a signal and none of them found one; one found the opposite. If you have read that these drugs carry a suicidality warning, that was true, and it is not true now.
Where the concern came from
In 2023 European regulators opened an investigation after reports of suicidal thoughts in people taking semaglutide.[3] That was the right response to a safety signal: reports of that kind are exactly what post-marketing surveillance exists to catch, and the correct next step is to find out whether the drug is causing them or whether they would have occurred anyway in a large population.
There was also a plausible reason to worry. Bariatric surgery, the older standard treatment for obesity, has a small but real association with increased suicidality. A drug producing comparable weight loss raised a reasonable question about whether it might carry a comparable risk.
What the studies found
| Study | Design and size | Result |
|---|---|---|
| JAMA Psychiatry, 2025[1] | Meta-analysis of 27 randomized trials; 32,354 on a GLP-1 against 27,042 on placebo | 0.047 vs 0.042 events per 100 person-years — rate ratio 0.76 (95% CI 0.48–1.21) |
| JAMA Internal Medicine, 2024[2] | Swedish and Danish national registers; 124,517 GLP-1 users against 174,036 on an SGLT2 inhibitor | 77 vs 71 suicide deaths — HR 1.25 (0.83–1.88), not significant |
| Nature Medicine, 2024[3] | 240,618 adults with overweight or obesity, replicated in 1,589,855 with type 2 diabetes | Lower risk of suicidal ideation on semaglutide — HR 0.27 incident, 0.44 recurrent |
Read the register study past its headline. Suicide death alone showed no significant difference. The composite of suicide death and non-fatal self-harm came out lower on GLP-1 drugs, at a hazard ratio of 0.83 (95% CI 0.70–0.97). New diagnoses of depression and anxiety were flat, at 1.01 (0.97–1.06).[2]
Its authors also did what good studies do: they said how much uncertainty is left rather than declaring the matter closed. The upper bound of their confidence interval is compatible with an absolute increase of no more than 0.16 events per 1,000 person-years.[2] That is the ceiling on what the data can still hide.
The randomized evidence, pooled
A 2025 meta-analysis pooled 25 randomized controlled trials and found no significant association between these drugs and suicidal behavior: a risk ratio of 0.84 (95% CI 0.54–1.32, P = 0.46).[7]
What makes it unusually clean is the consistency. No subgroup reached significance, and every one had an I² of 0%, meaning no detectable variation between studies. The point estimates fall on both sides of 1, scattered around no effect: type 2 diabetes (0.74) and obesity (1.07), adolescents (0.91) and adults (0.84), suicidal ideation (1.04), attempts (0.68) and completed suicides (1.06), and each individual drug from dulaglutide (0.46) to lixisenatide (1.25).
What the label change says
Each of the three labels carries a Recent Major Changes table at the top, which records what was added or taken out and when. All three record the same thing in February 2026: the Suicidal Behavior and Ideation section, removed.[4][5][6]
Suicidal Behavior and Ideation (5.10) ……… (Removed) 02/2026— WEGOVY prescribing information, Recent Major Changes
A regulator removing a warning is a stronger statement than a regulator declining to add one. Warnings are cheap to keep and expensive to take off, because taking one off invites exactly the criticism a regulator least wants. It happened across three products in the same month.
What this does not settle
- Only 27 of 144 eligible trials systematically recorded these events.[1] The meta-analysis is built from the minority of trials that were looking, which is a real limitation and its authors say so.
- The register study is mostly people with type 2 diabetes, at a mean age of 60.[2] That is not the same population as a 38-year-old taking Wegovy for weight.
- Absence of a population signal is not a statement about you. A drug can fail to raise risk across 300,000 people and still be part of what is happening to one person.
- Continued monitoring is the authors’ own recommendation, not a formality, because extended use in far larger numbers is still accumulating.[1]
If your mood has changed since starting
Tell your prescriber, and do not talk yourself out of it because a study said the risk is not elevated. Population evidence describes populations. Rapid weight loss changes sleep, eating, hormones and how people relate to their bodies, and any of that can move mood without the drug acting on the brain directly.
Stopping abruptly is not obviously the answer either, and it is not a decision to make alone. The same goes for an antidepressant you already take, as covered in antidepressants and a GLP-1. What the evidence supports is telling someone, promptly, and letting a clinician who knows your history weigh it. If you are in crisis, 988 in the US is available now, and is the right first call rather than the last one.
Frequently Asked Questions
References
- 1.Ebrahimi P, Batlle JC, Ayati A, et al. Suicide and Self-Harm Events With GLP-1 Receptor Agonists in Adults With Diabetes or Obesity: A Systematic Review and Meta-Analysis JAMA Psychiatry. 2025. PMID: 40105856.
- 2.Ueda P, Söderling J, Wintzell V, et al. GLP-1 Receptor Agonist Use and Risk of Suicide Death JAMA Internal Medicine. 2024. PMID: 39226030.
- 3.Wang W, Volkow ND, Berger NA, et al. Association of semaglutide with risk of suicidal ideation in a real-world cohort Nature Medicine. 2024. PMID: 38182782.
- 4.Novo Nordisk Inc. WEGOVY (semaglutide) — US Prescribing Information, Recent Major Changes: Suicidal Behavior and Ideation (5.10) removed 02/2026 DailyMed (FDA-approved labeling). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
- 5.Eli Lilly and Company. ZEPBOUND (tirzepatide) — US Prescribing Information, Recent Major Changes: Suicidal Behavior and Ideation removed 02/2026 DailyMed (FDA-approved labeling). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
- 6.Novo Nordisk Inc. SAXENDA (liraglutide) — US Prescribing Information, Recent Major Changes: Suicidal Behavior and Ideation (5.9) removed 02/2026 (SPL effective 2026-02-25) DailyMed (FDA-approved labeling). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143
- 7.Chen J, Zhang Q, Wu Q, et al. Impact of GLP-1 Receptor Agonists on Suicide Behavior: A Meta-Analysis Based on Randomized Controlled Trials Journal of Diabetes. 2025. PMID: 40887719.
Compare the sellers
Related research
Exenatide (Byetta, Bydureon): The First GLP-1, Its Weight Loss and Where It Went
Exenatide, sold as Byetta and Bydureon BCise, was the first GLP-1 drug. It is approved only for type 2 diabetes, produces far less weight loss than semaglutide, and both brands are discontinued in the US. Its one generic is now listed as discontinued too.
10 min read
Dizzy on a GLP-1? The Blood-Pressure Question the Labels Skip
Dizziness affects 4% to 8% of people on the weight-loss doses. The labels tell prescribers to lower insulin or sulfonylurea doses, and say nothing about blood-pressure pills, though low blood pressure is more common in people taking them.
7 min read
GLP-1 Allergic Reactions and Anaphylaxis: What the Labels and Cases Show
True allergy to semaglutide or tirzepatide is real but rare: about 3.6 anaphylaxis cases per 10,000 person-years on semaglutide. What each label says, how antibodies and inactive ingredients fit in, whether another GLP-1 is safe after a reaction, and when to call 911.
11 min read
Why a GLP-1 Raises Your Heart Rate, and When Palpitations Matter
Every GLP-1 raises resting heart rate by a few beats a minute, but only Wegovy and Saxenda warn about it. What the labels show, why it happens, whether it matters, and the palpitations that point elsewhere.
9 min read
Ozempic, Wegovy and Zepbound While Breastfeeding: What the Labels Say
Ozempic's label does not forbid breastfeeding; the semaglutide tablets and Foundayo advise against it, and tirzepatide is the only GLP-1 with a human milk study on its label. Each label's lactation wording, LactMed's summaries and the small milk studies.
11 min read
Tirzepatide Week by Week: What the SURMOUNT Trials Recorded
The dose ladder takes months, not weeks. This sets out what SURMOUNT-1, 2 and 4 recorded at each stage on Zepbound and Mounjaro, and the roughly half of the lost weight that came back when people stopped.
7 min read
Where to get tirzepatide online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Bodybuilding Health+
Seeing what it charges before you answer any medical questions
From $209/mo
Get started →Embody
From $129/mo
Get started →Collective
From $69/mo + membership
Get started →